The results of these studies indicate that the expression of HER-2 in CRC is associated with the prognosis and may constitute a potential candidate for novel adjuvant therapies involving humanized monoclonal antibodies, such as Herceptin. The gene discussed is ERBB2; the disease is colorectal carcinoma.